001) and the disease duration (r = 0.235, P = 0.04), respectively. Patients with positive anti-Ro/SS-A and anti-La/SS-B antibodies had higher SCr levels compared to those with negative serology (r = 0.292, P = 0.009, and r = 0.259, P = 0.022, respectively). Nine patients with proteinuria and anti-Ro/SS-A, anti-La/SS-B positivity tended to have lower K and Mg levels which suggests subclinical renal tubular acidosis. There were no associations

between serum cysC levels and renal involvement in patients with pSS. However, in patients with proteinuria, serum cysC levels were correlated with acute-phase reactants, suggesting an association with disease activity in terms of degree of inflammation. “
“In recent years our understanding and interest in occult hepatitis B infection has increased manifold. To render uniformity to this ever-changing field, occult RO4929097 in vivo Hepatitis B infection (OHBI) was defined RG7204 solubility dmso at a recent consensus meeting as presence of Hepatitis B viral DNA (HBV DNA) in the

liver in individuals tested negative for Hepatitis B surface antigen (HBsAg).[1] These patients can, however, test positive for other serological markers like IgG antibody against Hepatitis B core (IgG anti HBc) and/or against surface antigen (IgG anti HBs). On the other hand, up to 20% of patients with OHBI can be negative for both the antibodies.[2] HBV DNA levels in patients with OHBI, even if detectable, is usually very low (< 200 IU/mL). Host immunity plays an important part in induction and maintenance of this occult status of Hepatitis B infection.[3] Thus, immunosupression induced by cancer chemotherapy or immunosuppressant drugs in patients with OHBI have a potential to reactivate Hepatitis B infection. The intensity of immunosuppression and its duration may determine the magnitude of the risk for

Hepatitis B re-activation in this scenario. Viral reactivation has been shown to be much higher in patients with HBsAg Akt inhibitor positive state (20–50%) as compared to those with OHBI.[4-6] This remains true for tumor necrosis factor targeted therapy in Hepatitis B infected patients as well.[7] In the study reported by Zhang et al.[8] in this issue, patients were included from a previous multicentric randomised controlled trial of Infliximab in Rheumatoid arthritis (RA). Baseline/on-treatment data of patients with OHBI in this cohort have been presented. In this study, 41 patients with OHBI were treated with five doses of Infliximab (at 0, 2, 6, 14, 22 weeks). All patients had received Methotrexate for at least 3 months, prior to starting Infliximab. The patients were followed up for 26 weeks (i.e. 4 weeks after the last Infliximab infusion). There was no significant rise in serum aminotransferase or bilirubin during therapy and at 26 weeks. Thirty of the 41 patients maintained HBsAg negative status when retested. This study thus demonstrated an excellent short-term safety of Infliximab therapy in RA patients with OHBI. In this study by Zhang et al.